A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

Inclusion Criteria:

• Have documented diagnosis of SCLE or CCLE that has been confirmed by biopsy with orwithout systemic LE manifestations.

• Have a total CLASI-A score of ≥10 at Screening and Day 1. Participants with aCLASI-A score of ≥8 and <10 are eligible if the score does not include alopeciaand/or mucous membrane lesions.

• Have active CLE despite an adequate trial of conventional therapies.

• Are positive for at least one autoantibody at Screening.

Exclusion Criteria:

• Have known or suspected drug-induced CLE anti-phospholipid disease, orneuropsychiatric SLE.

• Have rapidly progressive nephritis.

• Have current inflammatory skin disease other than SCLE/CCLE that, in the opinion ofthe Investigator, could interfere with the inflammatory skin assessments or confoundthe disease activity assessments.

Note: Other protocol defined Inclusion/Exclusion criteria may apply